Sickle Cell Disease Trial, Recruiting (NCT07356050)

Sickle Cell Disease Trial, Recruiting NCT07356050 Sponsor: Children's Hospital Medical Center, Cincinnati Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07356050 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You (or your child) must have a confirmed diagnosis of Sickle Cell Disease
The participant must be between 6 months and 6 years of age and be due for a measles vaccine within the next 3 months, based on national vaccination guidelines
You (or a parent/guardian) must be willing and able to give consent to take part in the trial
The participant must be able to attend follow-up visits and take part in study-related check-ups

Who may not be able to join:

Participants who have a known condition that severely weakens the immune system — such as a primary immune deficiency disorder, cancer, or AIDS — which would prevent them from safely receiving a live virus vaccine

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alexandra Power-Hays, MD, Children's Hospital Medical Center, Cincinnati

Phone: 513-803-7922

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07356050

Sponsor: Children's Hospital Medical Center, Cincinnati

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: 513-803-7922

More information: https://clinicaltrials.gov/study/NCT07356050

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You (or your child) must have a confirmed diagnosis of Sickle Cell Disease
The participant must be between 6 months and 6 years of age and be due for a measles vaccine within the next 3 months, based on national vaccination guidelines
You (or a parent/guardian) must be willing and able to give consent to take part in the trial
The participant must be able to attend follow-up visits and take part in study-related check-ups

Who may not be able to join:

Participants who have a known condition that severely weakens the immune system — such as a primary immune deficiency disorder, cancer, or AIDS — which would prevent them from safely receiving a live virus vaccine

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Children's Hospital Medical Center, Cincinnati

Registry

ClinicalTrials.gov

Start date

13 March 2025

Est. completion

31 December 2027

Where this trial is recruiting

Ghana Tanzania 🇺🇸 United States

Primary endpoints

Measles Seroconversion Rates 8 Weeks After MV1 and MV2 Vaccinations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov